Sydney, June 17, 2026, 06:22 AEST
- Cochlear closed Tuesday at A$106.86, up 2.31%. The stock earlier touched A$108.27, adding to its bounce from decade lows.
- UBS cut its price target to A$106 from A$109, holding its Neutral rating. The new target matches the stock’s recent level.
- Cochlear faces its next test with the full-year result due Aug. 18. After a profit outlook cut in April, investors are looking for more clarity on guidance.
Cochlear Limited climbed 2.31% to A$106.86 on Tuesday, logging another session in the green. The hearing-implant stock added again, despite UBS cutting its target. Trading for Wednesday has not started. The ASX cash market runs from just before 10 a.m. to 4 p.m. Sydney time.
Cochlear is still viewed as a large-cap under strain. The stock has bounced about 20% from its A$88.74 low but is down roughly 59% for the year. That’s from The Bull, citing recent broker notes.
S&P/ASX 200 ended Tuesday up 3.7 points at 8,917.70. The Reserve Bank of Australia left the cash rate unchanged at 4.35% and warned higher rates could be on the table if inflation remains sticky. Broader gains stayed limited.
Cochlear is still facing an uncertain earnings outlook. The company cut its FY26 underlying net profit guidance in April to between A$290 million and A$330 million, well below the previous A$435 million to A$460 million target. That’s based on management’s adjusted figures. Cochlear also put out a forecast for 2% to 6% sales growth in the second half, excluding currency moves.
Cochlear pointed to weak implant demand in developed markets, hospital caps, and fewer referrals through the hearing aid channel. The company also flagged continued Middle East uncertainty. Currency was another headwind, with a stronger Australian dollar and squeezed gross margins dragging on results. “We remain confident of our market leadership,” CEO and President Dig Howitt said.
UBS kept its Neutral rating and trimmed its price target to A$106 from A$109, a June 12 disclosure showed. The Bull wrote UBS cut FY26 and FY27 earnings by 2% to 3%, citing issues in the Middle East, U.S. payer pressure, and some trouble executing in Western Europe.
That partly explains the move up in shares Tuesday, but it also points to the ceiling. The target is close to the current price, and one major broker isn’t expecting much short-term upside unless Cochlear can show the delayed sales come back instead of disappearing for good.
Cochlear stays in a tough fight with rivals MED-EL and Sonova’s Advanced Bionics for implant market share. Surgeons matter and product uptake is key, but it also depends on reimbursement and how fast hospitals can move patients through.
Bigger problem for Cochlear would be if Middle East orders are cancelled rather than only delayed. U.S. Medicare Advantage approval delays and payer denials are still keeping procedures on hold. Western Europe is still working through surgical backlogs, and those could drag on. That could hold back the recovery. A stronger Australian dollar, something Cochlear has already flagged, would also cut into overseas earnings when brought home.
Cochlear set August 18 for its 2026 full-year results. The market is focused on FY27 guidance, trends in Services sales, and updates on Nucleus Nexa’s sales. Any increase in Middle East receivables will be watched closely. There’s also interest in the costs from shifting the business. For now, Cochlear shares are reacting more to questions left from April’s slump than anything from new earnings info.
